There is a moment many biotech investors know well. The chart looks bruised, sentiment has cooled, and the company suddenly has to prove that growth is still real rather than just promised. That is usually when the hardest question shows up: is this a temporary reset, or the start of something worse?

Telix Pharmaceuticals has spent the past year sitting right inside that tension. On one hand, this is no longer a tiny speculative biotech with no commercial engine. Telix finished FY2025 with US$803.8 million in revenue, up 56% year over year, and said that the result met its upgraded guidance. On the other hand, the market has had to process rising R&D spend, acquisition-related costs, regulatory bumps, and the usual volatility that comes with growth-stage healthcare names.

That is why the recent rebound in TLX has caught attention. ASX market data showed TLX at A$11.23, up 4.37% on the day in one of the latest market snapshots available, and the share-price recovery has coincided with stronger commercial numbers, the U.S. launch momentum of Gozellix, and a fresh clinical catalyst from the company’s ProstACT Global Phase 3 program.

Has the stock bottomed?

The honest answer is that Telix looks far more supported fundamentally than it did during its weaker patches, but calling a definitive bottom in biotech is always dangerous. What can be said with more confidence is this: the ingredients that usually help a stock stabilise are now visible. Revenue is real. Commercial execution is real. Pipeline milestones are still arriving. And the market is starting to price Telix less like a hope story and more like a company trying to build a durable radiopharmaceutical platform.

Who is Telix Pharmaceutical (ASX: TLX)?

Telix Pharmaceuticals is an Australian-headquartered biopharmaceutical company focused on radiopharmaceuticals, which are targeted medicines and imaging agents that use radioactive isotopes to diagnose or treat disease, particularly cancer. The company is listed on the ASX under the ticker TLX and on Nasdaq. Its core focus is oncology and rare diseases, with operations spanning Australia, the United States, Europe, Brazil, Canada, Japan, Switzerland and the UK. Click here to see all our latest articles about Telix Pharmaceutical (ASX: TLX).

That broad footprint matters more than it might seem at first glance. Many small-cap biotech names talk about global opportunities. Still, Telix has already built commercial operations around products on the market, while also investing in a broader late-stage pipeline. In plain English, this is no longer just a lab story. Telix is trying to be a scaled radiopharma business with diagnostics, therapeutics, manufacturing and distribution under one roof.

Its best-known commercial product is Illuccix, a prostate cancer imaging agent approved in multiple markets. Telix has also been expanding with Gozellix, another prostate cancer imaging product that the company says helped drive Q4 2025 precision medicine revenue growth after reimbursement in the United States became effective from 1 October 2025. That is an important detail because reimbursement often marks the line between a product being technically approved and being commercially meaningful.

The company’s business model has become more layered over time. It now reports across Precision Medicine, Therapeutics and Telix Manufacturing Solutions. That last segment includes manufacturing and distribution assets such as RLS Radiopharmacies, which Telix acquired to strengthen its vertically integrated supply chain. Anyone who has followed healthcare manufacturing knows how often supply bottlenecks destroy good product stories, so Telix’s push into infrastructure is not glamorous, but it is strategically important.

There is also the pipeline. Telix is not relying on one future drug to justify its valuation. The company has programs in prostate cancer, kidney cancer, brain cancer and bone-metastasis pain, alongside imaging and therapeutic candidates. At the January 2026 J.P. Morgan Healthcare Conference, Telix described 2026 as a “catalyst-rich” year, pointing to milestones across its therapeutic and precision medicine programs, as well as manufacturing expansion.

That phrase, “catalyst-rich,” gets overused in biotech, but in Telix’s case, it is backed by an unusually active calendar. The company has been advancing TLX591-Tx in prostate cancer, moving the BiPASS registration-enabling trial forward for Illuccix and Gozellix, progressing geographic expansion in China, and continuing work on kidney and brain cancer assets. Investors are essentially looking at a company that already has meaningful revenue, but still behaves like a pipeline stock in terms of news flow. That combination can be powerful when markets are optimistic and painful when they are not.

One thing that also stands out is how quickly Telix has scaled financially. In H1 2025, revenue reached US$390.4 million, up 63% year-over-year. By FY2025, full-year revenue had risen to US$803.8 million. That kind of growth does not remove risk, but it does change the conversation. Investors are no longer asking whether Telix can commercialise anything. They are asking whether it can convert commercial strength into sustainable margins while still funding an ambitious pipeline.

And that is really the Telix story in one sentence: a biotech that has crossed into commercial reality, but still carries the volatility of a pipeline-driven stock.

What Investors Should Know About TLX's Recent Lows

When a stock like TLX pulls back, the reason is rarely just one bad headline. It is usually a pile-up of issues that, together, make investors less willing to pay up for future growth.

For Telix, one pressure point was profitability optics. In H1 2025, the company reported strong revenue growth, but also a loss before tax of US$4.8 million. Management said that the figure included US$12.4 million in non-cash finance costs associated with convertible bonds issued in July 2024, as well as higher amortisation costs following the RLS acquisition. In other words, the business was growing fast, but the income statement did not look as clean as some investors might have hoped.

That pattern continued in the FY2025 result. Telix reported a non-material loss before tax of US$5.3 million, again driven by non-cash finance costs tied to convertible bonds and increased amortisation following the RLS acquisition. This is the sort of thing that can spook short-term holders even when management sees it as the price of scaling up. Markets are impatient. They like growth, but they like simple growth even more. Telix’s growth has not been simple.

Another factor behind the lows was heavy reinvestment. Telix spent US$81.6 million on R&D in H1 2025, up 47% year over year, and US$157.1 million across FY2025. That level of spending is logical for a company pushing multiple late-stage assets at once, but it also reminds investors that Telix is still in a capital-intensive phase. This is not a mature pharmaceutical company quietly harvesting cash flows. It is still building.

Then there was regulatory friction. In August 2025, Telix disclosed that TLX250-CDx, also known as Zircaix, had received a Complete Response Letter from the U.S. FDA. Later company updates made clear Telix was working through the resubmission process after discussions with the FDA. That did not destroy the broader Telix thesis, but it likely dented confidence because investors had been looking at Zircaix as another potential commercial lever. Regulatory setbacks do not have to be fatal to hurt a biotech stock. Sometimes they just inject doubt, and doubt alone can compress valuation.

There is a second layer here that investors often miss. Telix is no longer judged only on science. It is judged on execution across several moving parts at once: manufacturing, reimbursement, launches, acquisitions, margin management, and clinical development. That is a much harder standard to meet consistently. A company can be doing many things right and still see its share price wobble if even one of those pieces looks delayed or less profitable than expected.

That helps explain why recent lows should not automatically be read as a collapse in the business. The H1 result still showed a positive operating net cash flow of US$17.7 million and a cash balance of US$207.2 million even after substantial M&A investment. By FY2025, Telix will have US$141.9 million and US$246.4 million in remaining intrategic strategic investments. Those are not numbers that suggest a company in distress. They suggest a company spend aggressively to expand.

It is also worth remembering that biotech investors routinely punish companies for “good but not perfect” periods. A revenue beat can still be sold off if margins narrow. A pipeline update can still be ignored if another program hits a delay. I have seen this rhythm over and over with growth healthcare names: the stock drops not because the business broke, but because expectations got ahead of timing. Telix’s weaker periods looked more like a reset than a sign that the company’s commercial base was unravelling.

Another stabilising point is that the underlying Precision Medicine business remained profitable and commercially healthy. In H1 2025, Precision Medicine segment revenue was up 30% year over year, Illuccix gross margin remained stable at 64%, and adjusted EBITDA for the segment rose 24% to US$104.6 million. That matters because if a company has one strong engine generating cash while the rest of the platform is being built, the market is usually more forgiving over time.

So when investors look back at TLX’s recent lows, they should frame them properly. The decline was not just random market noise, but neither was it a clean verdict that the business is broken. It was a reaction to a messy but understandable mix: higher costs, reinvestment, regulatory noise, and the challenge of proving that rapid growth can be sustained without constant dilution of returns. That is uncomfortable, yes. But it is very different from a pure speculative biotech crash.

What is the reason for the recent increase in TLX prices, and will it continue?

The recent strength in TTLX comes from a much more constructive mix of fundamentals and catalysts.

Source: telixpharma.com

Strong revenue growth continues to support investor confidence

One of the most important drivers behind the recent share price strength is the company’s ability to keep delivering revenue growth. Telix’s Q4 2025 update reported full-year revenue of about US$804 million, comfortably within the upgraded guidance range of US$800 million to US$820 million.

Even more notable was the momentum into the end of the year. Fourth-quarter revenue reached US$208 million, representing a 46% year-over-year increase.

For investors, numbers like these send a clear signal. Earlier concerns that growth might slow have not materialised. Instead, Telix has continued to expand its commercial footprint, suggesting that demand for its precision medicine products remains strong.

In growth-oriented healthcare companies, consistent revenue delivery often becomes the foundation for share price recovery. When investors see that sales are still climbing, confidence tends to return gradually.

The launch of Gozellix is emerging as a commercial catalyst

Another important contributor to TLX’s recent momentum is the launch of Gozellix in the United States.

Telix reported that Q4 2025 precision medicine revenue was partly driven by the successful rollout of this prostate cancer imaging product, following reimbursement approval from the Centres for Medicare and Medicaid Services (CMS) effective 1 October 2025.

Reimbursement approvals are often the turning point for medical products. Without reimbursement, hospitals and clinicians may hesitate to adopt new technologies. Once reimbursement is secured, the commercial pathway becomes much clearer.

Interestingly, Telix also noted that revenue growth outpaced dose-volume growth. In simple terms, the company is not only selling more doses but may also be benefiting from improved pricing and market share through its two-product strategy.

That is an encouraging signal because it suggests stronger commercial leverage. Instead of relying on a single flagship product, Telix now has multiple imaging tools competing within the same market.

Positive clinical progress from TLX591-Tx strengthened sentiment

Clinical progress has also played a major role in the recent rally. In March 2026, Telix announced that Part 1 of the ProstACT Global Phase 3 study evaluating TLX591-Tx achieved its primary objectives. The trial demonstrated acceptable safety and tolerability, with no new safety signals identified.

For biotech investors, Phase 3 progress is a big deal. Late-stage clinical trials represent one of the final hurdles before regulatory submissions and potential commercialisation.

The company also confirmed that the study had already advanced to Part 2 in regions with regulatory approvals in place. This progression reduces some of the uncertainty surrounding the therapeutic program.

Whenever a late-stage oncology program shows positive momentum, markets tend to react quickly. It reinforces the perception that the pipeline still has meaningful value beyond the company’s existing products.

Expansion into new global markets strengthens long-term growth prospects

Another factor that has helped improve Telix's outlook is its continued push into international markets.

In January 2026, the company announced that China’s National Medical Products Administration (NMPA) accepted the New Drug Application for Illuccix, its prostate cancer imaging agent.

The submission included results from a pivotal Phase 3 study conducted in China. According to the data, the imaging agent demonstrated a 94.8% positive predictive value in patients with biochemical recurrence of prostate cancer.

Even more striking was the clinical impact. Telix reported that 67.2% of patients experienced a change in treatment management after undergoing the scan.

These types of results strengthen the case for broader global adoption. While investors may not immediately factor China revenue into near-term forecasts, regulatory progress in major markets reinforces the idea that Telix’s technology platform still has significant expansion potential.

Can the TLX rally continue?

The recent rally has been supported by a fairly convincing combination of fundamentals and catalysts. Telix now operates with a profile that many healthcare investors actively look for: growing commercial revenue, multiple approved products, late-stage pipeline assets, and expanding manufacturing infrastructure.

That said, share price recoveries in the biotech sector rarely move in a straight line. For the rally to continue sustainably, investors will likely focus on three key areas.

First, commercial growth must remain strong. Continued adoption of Illuccix and Gozellix will be essential in demonstrating that Telix’s core business can generate durable revenue.

Second, pipeline milestones must continue to arrive. Programs like TLX591-Tx will play an important role in determining how large Telix’s future therapeutic portfolio might become.

Third, investors will eventually want to see improving earnings quality. Rapid revenue growth is encouraging, but markets typically reward companies even more when that growth begins translating into stronger profitability and operating leverage.

If Telix continues to make progress on these fronts, the recent recovery could evolve into a more stable long-term uptrend.

The risks investors should still keep in mind

Despite the improving outlook, Telix is still operating in a sector known for volatility.

Biotechnology companies face several ongoing risks. Regulatory approvals can take longer than expected, clinical trials can produce mixed results, and manufacturing expansion can temporarily pressure margins.

Another reminder of this uncertainty is the regulatory path of Zircaix (TLX250-CDx). The program previously received a Complete Response Letter from the U.S. FDA, highlighting that even promising technologies can encounter regulatory delays.

Events like this do not necessarily undermine the broader business, but they can affect investor sentiment, particularly when expectations are high.

Is TLX forming a long-term bottom?

The recent improvement in Telix’s share price suggests the market may be reassessing the company’s outlook. The stock no longer looks like a company under severe pressure. Instead, it appears to be transitioning into a phase where investors are weighing its commercial momentum against the remaining execution risks. That distinction matters.

A true bottom rarely forms overnight. More often, it emerges gradually as new information challenges the negative narrative that previously dominated the market.

In Telix’s case, several elements are beginning to support that shift: strong revenue growth, successful product launches, positive clinical progress, and expanding international opportunities.

None of these factors guarantees that the share price will never revisit lower levels. Markets can retest confidence, especially in healthcare.

But the overall picture appears stronger than during earlier periods of uncertainty. Telix now has multiple pillars supporting its story, rather than relying on a single product or a single clinical milestone. And that is often how long-term recoveries begin, not with a dramatic turning point, but with a series of small improvements that slowly rebuild investor trust.

Important Disclaimer: You’re reading a free article that offers general opinions and insights. For exclusive, in-depth research, timely high-conviction investment ideas, and actionable trade signals designed to help you stay ahead, join Proactive Equities today by opening a Free Trial Account now! (No Credit Card Required)

Technical Analysis of Pharmaceutical's (ASX: TLX)

Telix Pharmaceutical's (ASX: TLX) share price forecast

Source: Tradingview

Telix Pharmaceuticals (ASX: TLX) appears to be recovering after a long downtrend that started late last year. The stock declined from around $17 to a low near $8.80, where buyers finally stepped in and created a strong support zone.

Trend and Momentum

The most important technical change is the formation of higher lows since late February. After touching the $8.80–$9.00 area, TLX began printing stronger green candles and rising volume, which usually indicates accumulation by buyers. The recent move back above $10.50 suggests the short-term trend has shifted from bearish to neutral, with the potential to become bullish if momentum continues to build.

Key Support Levels

The chart shows two clear support zones:

$9.80 – $10.00: Near-term support where buyers recently defended the price.

$8.80 – $9.00: Major support and the recent swing low.

If the price falls below $9.80 again, the recovery may lose strength.

Resistance and Price Targets

The next important resistance sits around $11.50 – $12.00, where the price stalled several times previously. If TLX breaks and holds above this level, the next upside targets could be:

$12.80 – $13.00 (first technical target)

$13.80 – $14.00 (stronger resistance zone from December)

Suggested Stop-Loss

A reasonable stop-loss level for short-term traders would be around $9.70, slightly below the recent support area.

TLX is forming a potential base, but confirmation will come only if the stock can break and sustain levels above $12.00.

FAQs About Telix Pharmaceuticals (ASX: TLX)

1- Why has Telix Pharmaceuticals (ASX: TLX) share price been volatile recently?

Telix’s share price volatility mainly reflects the typical dynamics of biotech companies. Investors closely react to clinical trial results, regulatory updates, product launches, and financial performance. Over the past year, factors such as increased R&D spending, regulatory developments, and market expectations around pipeline progress have contributed to price fluctuations.

2- What are the main growth drivers for Telix Pharmaceuticals?

The company’s growth is largely supported by strong revenue from its prostate cancer imaging products, including Illuccix and Gozellix. In addition, Telix has a late-stage pipeline of radiopharmaceutical therapies and diagnostics, such as TLX591-Tx, which could expand its market opportunity if clinical trials and regulatory approvals progress successfully.

3- Could Telix Pharmaceuticals’ share price continue to rise in the future?

Future share price performance will likely depend on several factors, including continued commercial growth, successful clinical trial outcomes, and regulatory approvals in new markets. If Telix maintains strong revenue momentum and advances its pipeline, investor confidence may improve further, potentially supporting long-term share price growth.